Company intelligence / Profile preview

IHP Therapeutics

San Carlos, California, United Statesihptherapeutics.com ↗

Ownership: Private
Employees: ~10
Development stage: Preclinical

Overview

IHP Therapeutics is developing novel therapeutics including IHP-102, a dual P-selectin and complement inhibitor for sickle cell disease, and IHP-101 for solid tumors. The company also has IHP-009, a Phase 3 ready molecule for COVID-19 treatment.

Therapeutic areas: OncologyInfectious DiseasesHematology
Modalities: Small molecule drugGlycans
Industry: Biotech

Drug pipeline

2 assets

IHP-101

Preclinical

1 more asset in the full pipeline.

Request access →

Beyond the preview

Go deeper on IHP Therapeutics.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on IHP Therapeutics.

Explore the full profile